Performance analysis of Lexeo Therapeutics (LXEO)
Annual Return
Since Nov 3, 2023, LXEO has had an average annual return of -26.73%, underperforming the benchmark SPY, which returned +25.27% annual.
| 2026 | 2025 | 2024 | 2023 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -54.68% | +50.92% | -50.97% | +33.53% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -25.38% | -3.11% | -20.06% | -0.77% | -9.76% | -12.44% | -54.68% | ||||||
| 2025 | -17.47% | -47.33% | +21.33% | +13.23% | -30.79% | +47.82% | +17.65% | +1.27% | +38.63% | +50.75% | -1.50% | +0.71% | +50.92% |
| 2024 | +27.72% | -14.71% | +7.25% | -20.60% | +33.57% | -3.55% | -21.75% | -8.29% | -21.46% | -12.61% | +4.17% | -20.05% | -50.97% |
| 2023 | +26.57% | +5.50% | +33.53% |
Drawdown analysis of Lexeo Therapeutics (LXEO)
The maximum drawdown for the LXEO was -90.46%, occurring on Apr 7, 2025. This drawdown has not yet recovered.
The current LXEO drawdown is -76.01%.
Since Nov 3, 2023 LXEO has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 3 times
- 20% or more: 3 times
- 10% or more: 3 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -90.46% | Jun 13, 2024 | 203 | Apr 7, 2025 | Ongoing | Ongoing | Ongoing |
| -36.66% | Dec 5, 2023 | 4 | Dec 11, 2023 | 23 | Jan 16, 2024 | 27 |
| -30.47% | Jan 17, 2024 | 65 | Apr 19, 2024 | 33 | Jun 6, 2024 | 98 |
| -6.14% | Jun 10, 2024 | 1 | Jun 11, 2024 | 2 | Jun 13, 2024 | 3 |
| -3.88% | Nov 20, 2023 | 2 | Nov 22, 2023 | 3 | Nov 28, 2023 | 5 |
| -3.04% | Nov 9, 2023 | 2 | Nov 13, 2023 | 2 | Nov 15, 2023 | 4 |
| -1.15% | Jun 6, 2024 | 1 | Jun 7, 2024 | 1 | Jun 10, 2024 | 2 |
| -0.63% | Nov 16, 2023 | 1 | Nov 17, 2023 | 1 | Nov 20, 2023 | 2 |
| -0.38% | Nov 6, 2023 | 1 | Nov 7, 2023 | 1 | Nov 8, 2023 | 2 |